Innovative Bio-Pharmaceutical companies have long looked to China and India as reliable sources for manufacture of active pharmaceutical ingredient (API) and increasingly outsource pre-clinical and clinical Contract Research Organizations (CROs) in these markets. In a natural progression, as China and India move up the biotechnology value chain, Western bio-pharmaceutical companies may find considerable value research collaborations or other partnerships with Chinese and Indian counterparts. Not surprisingly, both China and India are facing “growing pains” associated with the rapid pace of development of their respective biotechnology markets, and are grappling with complex regulatory and legal reforms relating to IP protection and clinical research, among others.
This 90-minute webinar will provide an in-depth look at latest business trends in those countries, suggest strategies for partnering with local companies and provide an overview of the relevant patent laws. Don’t miss this chance to gain some added insight into two of the biggest emerging health care markets.
Learning Points:
- Discuss the current biotech business development trends in China and India
- Study patent regimes and related challenges for innovative bio-pharmaceutical companies conducting research in China and India
- Look at innovative drug development models in those areas and review biotech success stories
- Review latest foreign direct investment trends in China and India
Who Should Attend:
- CEOs, COOs, CFOs and other executive management
- General counsel and legal professionals
- Strategic planning and business development professionals
- Regulatory/legislative affairs professionals
About the Speakers:
Joel Papernik is a member in the Corporate & Securities Section of Mintz Levin, concentrating on corporate, commercial and securities matters, as well as strategic transactions and corporate structuring. He is a co-chair of the firm’s Mergers & Acquisitions Practice and a member of its Opinions Committee. Joel has extensive experience counseling high-technology businesses and the individuals creating them. He frequently guides acquisitions, collaborations and licensing domestic and international transactions in the biotechnology field. He has served as U.S. counsel to several overseas firms in connection with establishing operations, their conduct of public offerings and their acquisitions in the U.S. as well as overseas.
In recognition of his professional achievements, Joel was named a 2006, 2007, 2008, 2009, 2010 and 2011 New York Super Lawyer in The New York Times. He has been selected by his peers for inclusion in The Best Lawyers in America for his expertise in corporate law, and in 2006 was named one of "New York Area's Best Lawyers" in New York Magazine. He is the former chairman of the Corporation Law Committee of the Association of the Bar of the City of New York. He now serves on the Securities Law Committee of the New York State Bar Association, the TriBar Opinion Committee and the negotiated acquisitions committee of the American Bar Association. He is a member of the executive committee of the board of directors of the New York Biotechnology Association (NYBA), and a member of the Association of Commercial Finance Attorneys. Joel is a frequent lecturer on topics such as biotech-to-biotech acquisitions and dispositions, private placements and legal opinion matters, he and has conducted panels on India and China biotech.
Joel is admitted to practice in New York. He received his B.A. from Yale University and earned his J.D., cum laude, from Columbia Law School.
Mrs. Susan K. Finston, Esq., is Amrita Therapeutics’ CEO and managing director. In 2008, she co-founded Amrita Therapeutics Ltd. in Gujarat, India with biotechnology pioneer and serial bio-entrepreneur Ananda M. Chakrabarty, Ph.D. Susan brings to Amrita over 20 years of varied government and private sector legal experience, with particular expertise in biopharmaceutical policy, development and related intellectual property (IP) management. She has an extensive background in management of biopharmaceutical and drug development issues at the policy level, including in the IP and regulatory challenges facing biotechnology companies, and has particular expertise relating to India and diseases of the developing world.
In 2005 she launched Finston Consulting LLC as an independent consultancy to provide advice to innovative companies including start-up, strategic partnering, licensing, tech transfer, clinical drug development and policy advocacy. Previous experience includes six years at the Pharmaceutical Research and Manufacturers of America (PhRMA), where she was associate vice president for intellectual property, Middle East/Africa and South Asian Affairs. While at PhRMA, she led the international industry campaign for the successful amendment of India’s patent law to introduce product protection, and she worked with the Hashemite Kingdom of Jordan and the Kingdom of Saudi Arabia on WTO accession and related pharmaceutical IP, trade and investment issues.
From 1988 to 1999, she served in the U.S. Foreign Service, specializing in legal negotiations in areas of intellectual property, trade and development, and receiving two Meritorious Honor Awards for achievements in the areas of trade and development. She served in the judicial branch of the U.S. government for two years as a motions clerk at the federal Court of Appeals for the Seventh Circuit. Susan’s educational background includes a joint J.D./M.P.P awarded by the University of Michigan. She is a member of the Illinois Bar and the U.S. Supreme Court Bar.
A full listing of her board memberships, professional activities, awards and recent publications is available online at www.finstonconsulting.com.
